ElizabethKristineWeiheMD

Radiology • Baltimore, MD

Assistant Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Weihe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weihe's full profile

Already have an account?

Office
601 N Caroline St # 3142
Baltimore, MD 21287
Phone+1 410-955-6500

Education & Training

Baylor College of MedicineResidency, Radiology-Diagnostic, 2007 - 2011
Baylor College of MedicineClass of 2006

Certifications & Licensure

CA State Medical License 2015 - 2027
CO State Medical License 2024 - 2025
TX State Medical License 2008 - 2018
MD State Medical License 2010 - 2015
American Board of Radiology Diagnostic Radiology

Publications & Presentations

PubMed

Long-term treatment of metastatic adenoid cystic carcinoma with sequential brachytherapy and stereotactic body radiotherapy.
Allison Y Zhong, Sangwoo S Kim, Austin Hopper, Greg White, Sayuri Miyauchi
Radiation Oncology Journal. 2024-09-01
2 citations
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman
Breast Cancer Research. 2024-03-13
2 citations
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman
Breast Cancer Research. 2024-02-26

Abstracts/Posters

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Elizabeth K Weihe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Elizabeth K Weihe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/elizabeth-weihe